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have low positive predictive value, need further development,
and costs and consequences of screening are not fully known.
METHODS: We entered economic/clinical data and expert
opinion into a clinical decision model in order to compare: 1).
Targeted screening (TS) of children with one or more risk factors
for hearing disorders; 2). Universal neonatal hearing screening
(UNHS) by automated auditory brainstem response (AABR);
and 3). UNHS by otoacoustic emission (OAE) testing. RESULTS:
1). TS detected fewer than 15% of cases of bilateral hearing
impairment; 2). AABR-based UNHS was the most efﬁcient but
also costly strategy; and 3). OAE-based UNHS gave a higher
number of false positives than strategy two did. Results were sen-
sitive to prevalence, lost-to-follow-up rates, and costs. CON-
CLUSIONS: About 1 to 3 children/1000 in France are born with
at least moderate bilateral hearing impairment which should be
detected and treated early for normal development (speech, cog-
nitive and social functions). Our results for France conﬁrm pub-
lished data for other countries and can help our decision-makers
prioritize screening strategies. However, longer term dynamic
modeling is needed.
EAR—Patient Reported Outcomes
PER2
OUTCOMES ASSOCIATED WITH AN OTITIS PARENT
QUESTIONNAIRE IN PEDIATRIC PATIENTS WITH ACUTE
OTITIS MEDIA FOLLOWING ADMINISTRATION OF CEFDINIR
ORAL SUSPENSION OR HIGH DOSE
AMOXICILLIN/CLAVULANATE ORAL SUSPENSION
Schmier JK1, MacKinnon III GE2, Halpern MT1
1Exponent, Alexandria,VA, USA, 2Abbott Laboratories, Inc, Abbott
Park, IL, USA
OBJECTIVES: To compare parent-reported outcomes for chil-
dren receiving either cefdinir (Omnicef®) or amoxicillin/clavu-
lanate (Augmentin ES-600®) oral suspensions for the treatment
of acute otitis media. Outcomes of satisfaction, tolerability, com-
pliance and work/daycare missed were assessed using the Otitis
Parent Questionnaire (OPQ). METHODS: In a phase 4, single-
blind, parallel-group, randomized, multi-center study designed
to compare safety and efﬁcacy of cefdinir oral suspension (7
mg/kg/day every 12 hours for 10 days) to amoxicillin/clavulanate
oral suspension (90/6.4mg/kg/day amoxicillin base every 12
hours for 10 days), parents or legally authorized representatives
of patients were asked to complete the OPQ, 12–15 days after
the ﬁrst dose of treatment. RESULTS: The intent-to-treat popu-
lation included 311 patients, with a mean age of 37 months.
Parents reported signiﬁcantly better ease of use and taste in the
cefdinir vs. the amoxicillin/clavulanate treatment groups (both 
p < 0.0001); parents were satisﬁed or very satisﬁed with the ease
of use (89%) and with the taste of cefdinir (85%) as compared
with amoxicillin/clavulanate (57% and 39%, respectively). Chil-
dren were more likely to take their medication in the cefdinir
group compared to the amoxicillin/clavulanate group: parents
reported 82% of children took at least 95% of their doses of cef-
dinir, while 61% took at least 95% of the prescribed dose of
amoxicillin/clavulanate (p < 0.0001). Parent reported data sug-
gested that their children were signiﬁcantly more likely to expe-
rience diarrhea/loose stools in the amoxicillin/clavulanate group
than in the cefdinir group (28% vs. 18%; p = 0.0341). There
were no statistically signiﬁcant differences in work/daycare
missed. CONCLUSIONS: Based on parents’ assessments using
the OPQ, cefdinir was easier to administer and better tasting.
Children who received cefdinir experienced less vomiting and
diarrhea/loose stools. In addition, these children were reported
to be more compliant than those who received amoxicillin/
clavulanate.
EYE—Clinical Outcomes Studies
PEY1
PREVALENCE OF INTRAOCULAR HYPERTENSION AND
GLAUCOMA IN AN UNSELECTED FRENCH POPULATION
Bron A1,Thomas F2, Lefebvre S3, Levrat F3, Solesse De Gendre A4
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OBJECTIVES: In France, the prevalence of primary open angle
glaucoma has been estimated at 2% of the population over 40
years old. Given the limited data available, we prompted an epi-
demiological survey on the prevalence of ocular hypertension
and high pressure glaucoma in France. The principal objective
of this survey was to evaluate the prevalence of ocular hyper-
tension and high pressure glaucoma in subjects who were vol-
unteers for a health assessment, and to ﬁnd some risk factors.
METHOD: Clinical and laboratory data were collected during
the screening program, as well as information on the way of life,
and the personal and family medical history. All volunteers were
subjected to an intra ocular pressure, IOP recording with an air
tonometer. Those with an IOP above 21 mm Hg underwent a
FDT (frequence dubling technology) visual ﬁeld and a non
stereoscopic photograph with a digital non mydriatic camera.
Among 2797 subjects, 2165 subjects (i.e. 77.4%) agreed to par-
ticipate. Altogether, 2074 subjects (1384 men and 690 women)
were included in the study. RESULTS: Intraocular pressure >21
mmHg was observed in 10.1% of men and 6.4% of women. This
prevalence increased with age. Glaucoma was conﬁrmed in 2.2%
of men and in 3.0% of women. Prevalence of glaucoma in men
varied between 0.8% in the youngest subjects and 5.7% in sub-
jects over 60 years, and between 0.6% and 4.7%, respectively
in women. Logistic regression demonstrated that few parameters
of the health assessment could be linked to intraocular pressure
or glaucoma. CONCLUSION: This cross sectional study demon-
strated that there is a higher prevalence of ocular hypertension
and high pressure glaucoma than reported in currently published
data. This study did not reveal any major factors that could be
linked to ocular hypertension and glaucoma.
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PREVALENCE AND DESCRIPTION OF TREATMENT WITH
INTRAOCULAR PRESSURE LOWERING TOPICAL
MEDICATIONS IN CONTINENTAL FRANCE
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OBJECTIVES: The objective of the present study is to estimate
the prevalence of treatment with intraocular pressure (IOP) low-
ering topical medication in subjects aged 40 years or more in
continental France, and to describe the type of therapy, the com-
pliance and quality of life of the treated subjects. METHODS:
This is a telephone survey performed in general population on a
representative sample of 5726 subjects during the year 2004.
Subjects treated for glaucoma or HTO were deﬁned as those:
declaring using eye drops for more than one month and 1) citing
one of the 52 registered IOP-lowering topical medications,
and/or 2) declaring that they were taking the eye drops for glau-
coma or ocular hypertension (OHT). Quality of life was 
measured using the GlauQOL-17 questionnaire. RESULTS:
Globally, 237 subjects (4.1%) corresponded to this deﬁnition.
The prevalence increased with age, from 0.7% in subjects aged
40–44 years to 10.6% in those aged 80 years or more. 
Beta-blockers (49.5%) and prostaglandins (37.4%) were the
more frequent treatments, followed by carbonic anhydrase
inhibitors (15.3%), sympathomimetic mydriatics (5.7%) and
myotics (1.3%). Compliance was not total for 39% of the
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patients (22% of those treated with one-daily dosing). Those
subjects showed lower values in several dimensions of the quality
of life. This is a new way to estimate the GPAO and HTO preva-
lence. This allowed to give a useful approximation to profes-
sionals involved in ocular diseases medical, economical and
societal management. CONCLUSION: On the basis of this ﬁrst
nationwide study, it can be estimated that the prevalence of 
subjects treated with IOP-lowering topical medications is about
1.2 million in France. Number of daily doses appear to inﬂuence
compliance.
EYE—Cost Studies
PEY3
THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING
INTRAOCULAR LENSES ON AGE-RELATED MACULAR
DEGENERATION ASSOCIATED WITH CATARACT SURGERY
Reddy P1, Gao X2, Barnes R3, Fairchild C3, Boci K2,Waycaster C3,
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OBJECTIVES: Epidemiological data support an association
between age-related macular degeneration (AMD) and cataract
surgery that may be attributed to post-operative blue light expo-
sure. By limiting the retina’s blue light exposure, new blue-light
ﬁltering intraocular lenses (BLF IOLs) have the potential to
reduce the development of AMD following cataract surgery. In
the current economic healthcare environment, there is increased
interest in the cost-effectiveness of new medical technologies.
The objective of this analysis was to evaluate the cost-effective-
ness of a BLF IOL versus a non-BLF IOL in cataract surgery.
METHODS: An economic model was developed to emulate
three age-speciﬁc cohorts and to assess the clinical and economic
outcomes over 5 years. Data from the published literature was
supplemented with clinical expert opinion. Key clinical inputs
were the risk of AMD after cataract surgery and the effective-
ness of the BLF IOL in reducing the risk of AMD. Direct medical
costs including the cost of the IOL, monitoring, and AMD pro-
phylaxis and treatment were incorporated into the model. All
costs were standardized to 2004 US dollars. Age-stratiﬁed base-
case and sensitivity analyses were conducted. RESULTS: In the
BLF IOL group, the 5-year age-stratiﬁed incidence of AMD
ranged from 0.58 to 9.23 per 100 eyes, compared with 1.69 to
24.55 per 100 eyes in the non-BLF IOL group. The incremental
cost of the BLF was offset by reduced costs associated with
averted AMD treatment. Estimated savings with BLF IOLs per
100 eyes were $4275, $29,997, and $111,734 in the 55 to 64
year-old, 65 to 74 year-old, and ≥75-year-old cohorts, respec-
tively; these ﬁndings remained robust across the sensitivity analy-
ses. CONCLUSION: This study suggests that the economic
beneﬁts of implanting BLF IOLs during cataract surgery are
observed in all patients although cost savings are greatest in
patients ≥75 years.
PEY4
EVALUATION OF DIRECT MEDICAL COST OF EXUDATIVE
AGE-RELATED MACULAR DEGENERATION IN PATIENTS IN
THE MEDICARE POPULATION
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OBJECTIVE: Exudative age-related macular degeneration
(AMD) is the most common cause of blindness among older
Americans in the United States. No substantive information on
costs for exudative AMD was found in the literature. This study
estimates incremental costs for the disease. METHODS: Seven
years (1994–2000) of 5% sample of Medicare medical claims
data from the Standard Analytical File (SAF) was used. We fol-
lowed AMD and control patients with an index date starting in
1996 for two years. Incremental cost was deﬁned as the excess
cost for exudative AMD cohort over that of an age-gender-
matched non-exudative-AMD group based on Medicare reim-
bursed expenditures. We also estimated the 10-year projected
cost using Medical Price Index. Cost from AMD related comor-
bid conditions, such as depression which could worsen as the
result of the progression in exudative AMD, were evaluated indi-
vidually. RESULTS: A total of 3059 wet AMD patients were
identiﬁed and a cohort of non-wet-AMD with same size was also
created. Two years’ incremental medical cost for wet AMD
patients compared to the controlled cohort is $2689, including
$485 (18%) for inpatient hospital, $1132 (42%) for outpatient
hospital, and $1034 (38%) for ofﬁce visits. The 10-year pro-
jected cost was $16,148, including $6795 for outpatient hospi-
tal and $6207 for ofﬁce visit. Incremental cost of depression
almost doubled 1 year after the diagnosis of wet AMD, increas-
ing from $64/year to $118/year. CONCLUSION: Excess cost for
wet AMD after initial diagnosis was substantial. This research
does not incorporate Medicaid covered expenses and out of
pocket costs. With the aging population and people living longer,
the economic burden of this disease will increase. This informa-
tion may help researchers and policy makers in assessing beneﬁt
and increase use of approved AMD therapies, such as Macugen
(pegaptanib sodium) to help determine the clinical and economic
beneﬁts to patients and society.
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(VISUDYNE®) COMPARED TO USUAL CARE IN THE
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OBJECTIVES: ARMD is the leading cause of blindness for
people aged 60 and over in the US, resulting in signiﬁcant visual
ﬁeld losses, and consequent occurrences of serious vision-related
conditions and events, reductions in health-related quality of life,
and economic costs. The research objective was to assess the
incremental cost-utility of Visudyne®, relative to usual care of
ARMD. METHODS: A Markov cohort model was developed to
simulate progressive loss of visual acuity, treatment alternatives
and consequent clinical events and costs. Efﬁcacy of Visudyne®
was based on pooled results of three two-year randomized
placebo-controlled trials, and extrapolated to a horizon of 15
years. Treatment was assumed to be discontinued after two
years. Extrapolation of clinical trial results for both the treat-
ment and usual care arms of the model were based on the usual
care outcomes. Patients were grouped based on lesion type and
size. Relative risks and costs of serious clinical events (e.g., hip
fractures, nursing home placement), and utilities associated with
levels of visual acuity were derived from the literature. Incre-
mental cost-effectiveness ratios (ICERs) were expressed as 2004
US dollars per quality-adjusted life year ($/QALY). One-way sen-
sitivity analyses were performed with respect to efﬁcacy, the pro-
portion of patients receiving treatment for the better-seeing eye,
and other clinical, utility, and cost parameters. RESULTS: The
ICER of Visudyne® was $35,200/QALY, and was most sensitive
to the proportion of patients whose treatment was in the better-
seeing eye, the source for utilities, and the distribution of patients
